vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and RBC Bearings INC (RBC). Click either name above to swap in a different company.
RBC Bearings INC is the larger business by last-quarter revenue ($461.6M vs $360.9M, roughly 1.3× LivaNova PLC). RBC Bearings INC runs the higher net margin — 14.6% vs 8.6%, a 6.0% gap on every dollar of revenue. On growth, RBC Bearings INC posted the faster year-over-year revenue change (17.0% vs 12.1%). RBC Bearings INC produced more free cash flow last quarter ($99.1M vs $50.2M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs 5.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Dover Corporation is an American conglomerate manufacturer of industrial products. The Downers Grove, Illinois-based company was founded in 1955. As of 2021, Dover's business was divided into five segments: Engineered Products, Clean Energy and Fueling, Imaging & Identification, Pumps & Process Solutions and Climate and Sustainability Technologies. Dover is a constituent of the S&P 500 index and trades on the New York Stock Exchange under the symbol DOV. Dover was ranked 448 in the 2024 Fortu...
LIVN vs RBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $461.6M |
| Net Profit | $30.9M | $67.4M |
| Gross Margin | 65.2% | 44.3% |
| Operating Margin | 11.8% | 22.3% |
| Net Margin | 8.6% | 14.6% |
| Revenue YoY | 12.1% | 17.0% |
| Net Profit YoY | -44.7% | 16.4% |
| EPS (diluted) | $0.57 | $2.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $461.6M | ||
| Q3 25 | $357.8M | $455.3M | ||
| Q2 25 | $352.5M | $436.0M | ||
| Q1 25 | $316.9M | $437.7M | ||
| Q4 24 | $321.8M | $394.4M | ||
| Q3 24 | $318.1M | $397.9M | ||
| Q2 24 | $318.6M | $406.3M | ||
| Q1 24 | $294.9M | $413.7M |
| Q4 25 | $30.9M | $67.4M | ||
| Q3 25 | $26.8M | $60.0M | ||
| Q2 25 | $27.2M | $68.5M | ||
| Q1 25 | $-327.3M | $72.7M | ||
| Q4 24 | $55.9M | $57.9M | ||
| Q3 24 | $33.0M | $54.2M | ||
| Q2 24 | $16.3M | $61.4M | ||
| Q1 24 | $-41.9M | — |
| Q4 25 | 65.2% | 44.3% | ||
| Q3 25 | 68.4% | 44.1% | ||
| Q2 25 | 67.8% | 44.8% | ||
| Q1 25 | 69.7% | 44.2% | ||
| Q4 24 | 68.2% | 44.3% | ||
| Q3 24 | 70.8% | 43.7% | ||
| Q2 24 | 68.7% | 45.3% | ||
| Q1 24 | 70.3% | 43.1% |
| Q4 25 | 11.8% | 22.3% | ||
| Q3 25 | 15.1% | 21.5% | ||
| Q2 25 | 15.4% | 23.2% | ||
| Q1 25 | 15.3% | 23.0% | ||
| Q4 24 | 11.5% | 21.7% | ||
| Q3 24 | 11.2% | 21.6% | ||
| Q2 24 | 12.6% | 24.0% | ||
| Q1 24 | 5.5% | 22.8% |
| Q4 25 | 8.6% | 14.6% | ||
| Q3 25 | 7.5% | 13.2% | ||
| Q2 25 | 7.7% | 15.7% | ||
| Q1 25 | -103.3% | 16.6% | ||
| Q4 24 | 17.4% | 14.7% | ||
| Q3 24 | 10.4% | 13.6% | ||
| Q2 24 | 5.1% | 15.1% | ||
| Q1 24 | -14.2% | — |
| Q4 25 | $0.57 | $2.13 | ||
| Q3 25 | $0.49 | $1.90 | ||
| Q2 25 | $0.50 | $2.17 | ||
| Q1 25 | $-6.01 | $2.33 | ||
| Q4 24 | $1.04 | $1.82 | ||
| Q3 24 | $0.60 | $1.65 | ||
| Q2 24 | $0.30 | $1.90 | ||
| Q1 24 | $-0.78 | $1.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $107.6M |
| Total DebtLower is stronger | $376.1M | $990.2M |
| Stockholders' EquityBook value | $1.2B | $3.3B |
| Total Assets | $2.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.31× | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $107.6M | ||
| Q3 25 | $646.1M | $91.2M | ||
| Q2 25 | $593.6M | $132.9M | ||
| Q1 25 | $738.4M | $36.8M | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | — | ||
| Q2 24 | $329.2M | $76.8M | ||
| Q1 24 | $309.2M | $63.5M |
| Q4 25 | $376.1M | $990.2M | ||
| Q3 25 | $434.5M | $1.1B | ||
| Q2 25 | $430.6M | $915.6M | ||
| Q1 25 | $628.2M | $920.1M | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | $1.2B |
| Q4 25 | $1.2B | $3.3B | ||
| Q3 25 | $1.2B | $3.2B | ||
| Q2 25 | $1.1B | $3.1B | ||
| Q1 25 | $1.0B | $3.0B | ||
| Q4 24 | $1.3B | $2.9B | ||
| Q3 24 | $1.3B | $2.9B | ||
| Q2 24 | $1.2B | $2.8B | ||
| Q1 24 | $1.2B | $2.8B |
| Q4 25 | $2.6B | $5.1B | ||
| Q3 25 | $2.6B | $5.1B | ||
| Q2 25 | $2.5B | $4.8B | ||
| Q1 25 | $2.6B | $4.7B | ||
| Q4 24 | $2.5B | $4.7B | ||
| Q3 24 | $2.5B | $4.7B | ||
| Q2 24 | $2.5B | $4.7B | ||
| Q1 24 | $2.5B | $4.7B |
| Q4 25 | 0.31× | 0.30× | ||
| Q3 25 | 0.38× | 0.34× | ||
| Q2 25 | 0.38× | 0.29× | ||
| Q1 25 | 0.61× | 0.30× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | 0.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $122.1M |
| Free Cash FlowOCF − Capex | $50.2M | $99.1M |
| FCF MarginFCF / Revenue | 13.9% | 21.5% |
| Capex IntensityCapex / Revenue | 8.9% | 5.0% |
| Cash ConversionOCF / Net Profit | 2.67× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $122.1M | ||
| Q3 25 | $85.1M | $88.4M | ||
| Q2 25 | $62.9M | $120.0M | ||
| Q1 25 | $24.0M | — | ||
| Q4 24 | $78.7M | $84.0M | ||
| Q3 24 | $51.0M | — | ||
| Q2 24 | $43.4M | $97.4M | ||
| Q1 24 | $10.0M | — |
| Q4 25 | $50.2M | $99.1M | ||
| Q3 25 | $62.2M | $71.7M | ||
| Q2 25 | $47.8M | $104.3M | ||
| Q1 25 | $13.2M | — | ||
| Q4 24 | $68.3M | $73.6M | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $31.2M | $88.4M | ||
| Q1 24 | $3.6M | — |
| Q4 25 | 13.9% | 21.5% | ||
| Q3 25 | 17.4% | 15.7% | ||
| Q2 25 | 13.6% | 23.9% | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 21.2% | 18.7% | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 9.8% | 21.8% | ||
| Q1 24 | 1.2% | — |
| Q4 25 | 8.9% | 5.0% | ||
| Q3 25 | 6.4% | 3.7% | ||
| Q2 25 | 4.3% | 3.6% | ||
| Q1 25 | 3.4% | 3.2% | ||
| Q4 24 | 3.2% | 2.6% | ||
| Q3 24 | 5.7% | 4.1% | ||
| Q2 24 | 3.8% | 2.2% | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 2.67× | 1.81× | ||
| Q3 25 | 3.18× | 1.47× | ||
| Q2 25 | 2.32× | 1.75× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | 1.45× | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | 1.59× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
